Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Trying to improve your health and wellness in 2026? Keep it simple - 2U.S. overhauls childhood vaccine schedule, recommends fewer shots
- 3Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- 4Which camera do you believe is great for first-time clients? !
- 5Go With The Breeze: Grand Paragliding Spots On the planet
- 6 Fun Urban areas For Seniors To Travel
- How a toxic self-improvement trend with a funny name took over your feed
- Israeli girl suffers cardiac arrest during sirens in Safed, hospitalized in serious condition
- Black Friday Paramount+ deal: Save 50% and stream these buzzy Taylor Sheridan shows
- Heartfelt Objections to Visit with Your Adored One
- Iran war drives global fertilizer prices up, raising food cost fears
- Figure out How to Modify Your Pre-assembled Home for Greatest Solace and Stylish Allure
- Defense Minister Katz finally condemns Jewish extremist violence against Palestinians
- 'Euphoria' Season 3 trailer includes Eric Dane's final appearance, Jacob Elordi and Sydney Sweeney at the altar and Rue's 'Breaking Bad' era
